Orion Oyj A (ORNAV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Orion Oyj A (ORNAV) has a cash flow conversion efficiency ratio of 0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€79.50 Million ≈ $92.94 Million USD) by net assets (€919.60 Million ≈ $1.08 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Orion Oyj A (ORNAV) total market value for the company's overall valuation and market capitalisation.
Orion Oyj A - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Orion Oyj A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Orion Oyj A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orion Oyj A ranked by their cash flow conversion efficiency. Explore Orion Oyj A cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Wanfeng Auto Wheel Co Ltd
SHE:002085
|
0.006x |
|
Shanghai Daimay Auto Interior
SHG:603730
|
0.049x |
|
Veidekke ASA
OL:VEI
|
0.397x |
|
Rush Enterprises A Inc
NASDAQ:RUSHA
|
0.038x |
|
Orion Corp
KO:271560
|
0.053x |
|
COSCO SHIPPING Energy Transportation Co. Ltd
F:HIFH
|
0.072x |
|
Vale Indonesia Tbk
JK:INCO
|
-0.006x |
|
Ultra Clean Holdings Inc
NASDAQ:UCTT
|
-0.057x |
Annual Cash Flow Conversion Efficiency for Orion Oyj A (2004–2024)
The table below shows the annual cash flow conversion efficiency of Orion Oyj A from 2004 to 2024. View Orion Oyj A stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.00 Billion ≈ $1.17 Billion |
€293.40 Million ≈ $343.02 Million |
0.292x | +118.37% |
| 2023-12-31 | €890.10 Million ≈ $1.04 Billion |
€119.00 Million ≈ $139.12 Million |
0.134x | -72.05% |
| 2022-12-31 | €908.10 Million ≈ $1.06 Billion |
€434.40 Million ≈ $507.86 Million |
0.478x | +65.86% |
| 2021-12-31 | €747.90 Million ≈ $874.37 Million |
€215.70 Million ≈ $252.18 Million |
0.288x | -29.48% |
| 2020-12-31 | €731.30 Million ≈ $854.97 Million |
€299.10 Million ≈ $349.68 Million |
0.409x | +17.72% |
| 2019-12-31 | €779.40 Million ≈ $911.20 Million |
€270.80 Million ≈ $316.59 Million |
0.347x | +16.33% |
| 2018-12-31 | €773.10 Million ≈ $903.84 Million |
€230.90 Million ≈ $269.95 Million |
0.299x | -11.12% |
| 2017-12-31 | €679.70 Million ≈ $794.64 Million |
€228.40 Million ≈ $267.02 Million |
0.336x | -13.52% |
| 2016-12-31 | €641.10 Million ≈ $749.51 Million |
€249.10 Million ≈ $291.22 Million |
0.389x | -9.32% |
| 2015-12-31 | €594.90 Million ≈ $695.50 Million |
€254.90 Million ≈ $298.00 Million |
0.428x | -25.64% |
| 2014-12-31 | €514.90 Million ≈ $601.97 Million |
€296.70 Million ≈ $346.87 Million |
0.576x | +37.60% |
| 2013-12-31 | €513.90 Million ≈ $600.80 Million |
€215.20 Million ≈ $251.59 Million |
0.419x | -3.14% |
| 2012-12-31 | €511.20 Million ≈ $597.65 Million |
€221.00 Million ≈ $258.37 Million |
0.432x | +8.68% |
| 2011-12-31 | €500.00 Million ≈ $584.55 Million |
€198.90 Million ≈ $232.54 Million |
0.398x | -11.08% |
| 2010-12-31 | €467.40 Million ≈ $546.44 Million |
€209.10 Million ≈ $244.46 Million |
0.447x | -3.99% |
| 2009-12-31 | €439.10 Million ≈ $513.35 Million |
€204.60 Million ≈ $239.20 Million |
0.466x | +35.07% |
| 2008-12-31 | €418.60 Million ≈ $489.39 Million |
€144.40 Million ≈ $168.82 Million |
0.345x | +2.25% |
| 2007-12-31 | €447.30 Million ≈ $522.94 Million |
€150.90 Million ≈ $176.42 Million |
0.337x | +83.36% |
| 2006-12-31 | €443.50 Million ≈ $518.50 Million |
€81.60 Million ≈ $95.40 Million |
0.184x | -38.23% |
| 2005-12-31 | €581.80 Million ≈ $680.19 Million |
€173.30 Million ≈ $202.61 Million |
0.298x | -22.89% |
| 2004-12-31 | €479.70 Million ≈ $560.82 Million |
€185.30 Million ≈ $216.64 Million |
0.386x | -- |
About Orion Oyj A
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more